University Hospitals Case Medical Center (UHCMC) and Case Western Reserve University School of Medicine are part of a nationwide research study to determine the safety and effectiveness of a new smallpox vaccine geared toward adults ages 18 to 34 who have never been vaccinated against the disease.
The study is the first of its type in Northeast Ohio.
The current FDA-approved vaccine, Dryvax", is not recommended for use on everyone because of the potential for serious side effects in certain individuals. "For example, the current vaccine cannot be used in immune-compromised individuals, such as patients with HIV or individuals with certain skin conditions such as eczema," says Robert A. Salata, M.D., chief of the Division of Infectious Diseases at Case Western Reserve University School of Medicine and UHCMC.
The new vaccine, IMVAMUNE", is different from Dryvax, in that it contains a more weakened form of the live-virus within the vaccine.
"Because the vaccine is weakened, the side effects should be minimized enough to give the vaccine to all individuals, even those whose immune systems are suppressed," says Dr. Salata. "Our hope is that the new vaccine will be a safer alternative to the current vaccine."
UHCMC and the School of Medicine will act as a subunit of St. Louis University's Center for Vaccine Development, which is one of seven national testing sites known as Vaccine and Treatment Evaluation Units (VTEUs), designated by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.